Y. Khor (Melbourne (VIC), Australia), F. Luppi (Modena, Italy)
This session is built from abstracts published on the ERS Congress platform from 23 August, in an e-poster pdf format with a 3-minute audio narration. Participants and chairs of the session are invited to access all e-posters from 23 August to 4 September prior to the 1-hour live, online discussion scheduled from September 5-7. Please note that during live discussion there will be NO e-poster/abstract presentations, only discussion.
The effect of heated humidified nasal high flow oxygen supply on exercise tolerance in patients with interstitial lung disease.
Y. Al Chikhanie (Grenoble, France), D. Veale (Dieulefit, France), F. Hérengt (Dieulefit, France), S. Verges (Grenoble, France)
|   |
The corelation between exercise capacity and pulmonary hypertension in different types of ILD in a tertiary care center in India.
K. Devi (Pune, India), M. Modi (Pune, India)
| |
The role of incremental shuttle test after SARS-CoV2 infection
D. Badenes Bonet (Barcelona, Spain), D. Rodríguez Chiaradia (Barcelona, Spain), A. Rodó Pin (Barcelona, Spain), O. Caguana Vélez (Barcelona, Spain), C. Cumplí Gargallo (Barcelona, Spain), R. Chalela Rengifo (Barcelona, Spain), M. Admetlló Papiol (Barcelona, Spain), F. Zuccarino (Barcelona, Spain), D. Ramal Leiva (Barcelona, Spain), E. Balcells Vilarnau (Barcelona, Spain)
| |
Correlation of the Distance Saturation Product with spirometric and Diffusion Capacity for Carbon Monoxide data in patients with Interstitial Lung disease
K. Kchaou (Ariana, Tunisia), S. Khaldi (Ariana, Tunisia), A. Chaker (Ariana, Tunisia), S. Mokaddem (Ariana, Tunisia), S. Jameleddine (Ariana, Tunisia)
| |
Impact of early referral to palliative care in patients with interstitial lung disease
A. Rodrigo Troyano (Palma, Spain), A. Alonso (Barcelona, Spain), S. Barril (Lleida, Spain), O. Fariñas (Barcelona, Spain), E. Güell (Barcelona, Spain), A. Pascual (Barcelona, Spain), D. Castillo (Barcelona, Spain)
| |
Diaphragm ultrasound in patients with interstitial lung disease (ILD): a prospective study.
N. Bernardinello (Padova, Italy), A. Boscolo (Padova, Italy), E. Cocconcelli (Padova, Italy), N. Sella (Padova, Italy), G. Andreotti (Padova, Italy), F. Rea (Padova, Italy), M. Saetta (Padova, Italy), P. Navalesi (Padova, Italy), P. Spagnolo (Padova, Italy), E. Balestro (Padova, Italy)
| |
An international survey on genetics in clinical practice for interstitial lung disease.
M. Terwiel (Nieuwegein, Netherlands), R. Borie (Paris, France), B. Crestani (Paris, France), L. Galvin (Gentbrugge, Belgium), F. Bonella (Essen, Germany), A. Fabre (Dublin, Ireland), A. Froidure (Louvain, Belgium), M. Griese (München, Germany), J. Grutters (Nieuwegein, Netherlands), K. Johannson (Calgary, Canada), C. Kannengiesser (Paris, France), L. Kawano (Paris, France), M. Molina-Molina (Barcelona, Spain), A. Prasse (Hannover, Germany), E. Renzoni (London, United Kingdom), J. Van Der Smagt (Utrecht, Netherlands), V. Poletti (Forli, Italy), K. Antoniou (Heraklion, Greece), C. Van Moorsel (Nieuwegein, Netherlands)
| |
Assessment of alveolar-capillary membrane permeability using Tc99m – DTPA aerosols in diffuse systemic sclerosis – a cross sectional study
M. Bai (Pondicherry, India), D. Prakash Dwivedi (Pondicherry, India), G. Vishnukanth (Pondicherry, India), N. Pandit (Pondicherry, India), K. Chengappa (Pondicherry, India), A. Subathra (Pondicherry, India), R. Sivaranjini (Pondicherry, India)
| |
Analysis of patients with interstitial lung disease associated to Systemic Sclerosis treated with cyclophosphamide.
L. Arreguy Nogueira (Belo Horizonte (MG), Brazil), E. Mancuzo (Belo Horizonte (MG), Brazil)
| |
Associations between comorbidities and survival in patients with interstitial lung diseases
T. Znegui (sfax, Tunisia), M. Nadia (Sfax, Tunisia), N. Mahmoud (Sfax, Tunisia), K. Amina (Sfax, Tunisia), K. Nesrin (Sfax, Tunisia), G. Rahma (Sfax, Tunisia), B. Najla (Sfax, Tunisia), F. Walid (Sfax, Tunisia), M. Sameh (Sfax, Tunisia), Y. Ilhem (Sfax, Tunisia), A. Hajer (Sfax, Tunisia), K. Wajdi (Sfax, Tunisia), K. Sami (Sfax, Tunisia)
| |
Prevalence and quantification of thoracic pain (TP) through quantitative sensory testing (QST) in patients with chronic interstitial lung disease (cILD)
M. Scherer (Essen, Germany), S. Kampe (Essen, Germany), G. Weinreich (Essen, Germany), U. Costabel (Essen, Germany), F. Bonella (Essen, Germany)
| |
Interstitial lung disease associated with systemic lupus erythematosus : a monocentric study of 23 cases.
l. deneuville (paris, France), K. Sacre (paris, France), M. Debray (paris, France), P. Nicaise-Roland (paris, France), B. Crestani (paris, France), R. Borie (paris, France)
| |
Subclinical structural or functional lung changes is associated with higher risk of developing lower respiratory tract infection in a tertiary RA cohort.
B. Worcester (Melbourne, Australia), D. Wang (Melbourne, Australia), M. Leech (Melbourne, Australia)
| |
Pulmonary disease associated with rheumatoid arthritis
M. de Sousa Moreira (Lisboa, Portugal), A. Magalhães (Lisboa, Portugal), S. Silva (Lisboa, Portugal), A. Borba (Lisboa, Portugal), J. Cardoso (Lisboa, Portugal)
| |
Late Breaking Abstract - Characteristics of Post-COVID-19 interstitial lung syndrome in Bronchoalveolar Lavage: Preliminary results.
E. Tsitoura (Heraklion (Crete), Greece), S. Mastrodimou (Heraklion (Crete), Greece), E. Vasarmidi (Heraklion (Crete), Greece), I. Lampiri (Heraklion (Crete), Greece), K. Karagiannis (Heraklion (Crete), Greece), V. Stamatopoulou (Heraklion (Crete), Greece), N. Tzanakis (Heraklion (Crete), Greece), K. Antoniou (Heraklion (Crete), Greece)
| |
Late Breaking Abstract - Prognostic value of serum biomarkers in patients with idiopathic pulmonary fibrosis and correlation with disease progression.
K. Domvri (Thessaloniki, Greece), A. Apostolopoulos (Thessaloniki, Greece), I. Organtzis (Thessaloniki, Greece), E. Fouka (Thessaloniki, Greece), L. Bina (Thessaloniki, Greece), T. Kontakiotis (Thessaloniki, Greece), D. Papakosta (Thessaloniki, Greece)
| |